We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

By LabMedica International staff writers
Posted on 05 May 2025

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. More...

Syphilis, which can be transmitted sexually or from mother to infant during birth, is a treatable infection, but only if diagnosed early. If left untreated, syphilis can advance from painless sores to severe damage in the brain and cardiovascular system. Despite being first documented over 500 years ago — with some experts suggesting it may have affected humans for thousands of years — there is still no fast, reliable test to detect active syphilis infection. The disease often mimics symptoms of various other sexually transmitted and infectious conditions, making it challenging to diagnose and treat. Now, a collaborative project is working on a one-step confirmatory laboratory test designed to definitively diagnose active syphilis infection in just 10 minutes.

Accurately diagnosing syphilis requires identifying a range of symptoms, reviewing medical and sexual history, and performing several lab tests. When a person is infected, the body produces antibodies to fight the bacterium Treponema pallidum, which causes syphilis. These antibodies are produced whether the person is showing symptoms or not. Known as treponemal-specific antibodies, they can remain in a person’s system for decades, even if the infection is never active or after it has been successfully treated, making them unreliable for detecting an active infection. The body may also produce non-treponemal antibodies in response to active infection; however, this reaction is not exclusive to syphilis, so doctors must test for both types of antibodies to make a more accurate diagnosis and choose an appropriate treatment. While there are only two FDA-approved syphilis rapid tests, these detect only treponemal-specific antibodies, which could be from an infection that was treated years ago.

To definitively diagnose an active syphilis infection and determine the best treatment, clinicians need to test for non-treponemal antibodies that signal current infection, ideally obtaining semi-quantitative results. This involves counting the number of antibodies in a blood sample, a process that typically takes two to seven days and requires specialized equipment, meaning the tests are generally sent to a lab rather than being done in the doctor’s office. This approach is necessary to ensure high sensitivity and low false-positive rates when determining appropriate treatment. Researchers from The Pennsylvania State University (University Park, PA, USA) are now developing a platform that combines treponemal and non-treponemal assays to offer a more definitive, stand-alone diagnosis of syphilis.

The proposed platform utilizes highly sensitive electrochemical sensors that detect changes in current caused by the interaction between both types of antibodies and biological materials released from the bacterium or damaged host cells. The sensors are made from graphene, an atomically thin material that is highly responsive to these changes. These sensors can detect and quantify various proteins or molecules linked to these interactions. In initial tests using commercially available blood serum samples, the researchers found that the sensors could detect both antibody types in less than 10 minutes with high sensitivity. Once testing and refinement of their platform are complete, the team plans to develop a blood sample extraction device paired with a simple reader, similar to an at-home glucose meter, which will provide results in 10 minutes.

“This is the first study using electrochemical sensor for an integrated assay — or comprehensive test to detect multiple targets — for highly sensitive, rapid, point-of-care detection of both treponemal and non-treponemal antibodies needed to accurately diagnose active syphilis infection,” said Penn State Professor Dipanjan Pan. “Our goal is to simultaneously detect and quantify these antibodies, identifying and differentiating active from past cases of syphilis within 10 minutes to fulfill an urgent, unmet global need.”


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR System
OnePCR
New
Giardia Assay
AccuDiag Giardia
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.